U.S. regulators have approved the first digital pill with an embedded sensor to track if patients are taking their medication properly, marking a significant step forward in the convergence of healthcare and technology.The medicine is a version of Otsuka Pharmaceutical Co Ltd’s established drug Abilify for schizophrenia, bipolar disorder and depression, containing a tracking device developed by Proteus Digital Health.The system offers doctors an objective way to measure if patients are swallowing their pills on schedule, opening up a new avenue for monitoring medicine compliance that could be applied in other therapeutic areas.The FDA said that being able to track ingestion of medicines prescribed for mental illness may be useful “for some patients,” although the ability of the digital pill to improve patient compliance had not been proved.The system works by sending a message from the pill‘s sensor to a wearable patch, which then transmits the information to a mobile application so that patients can track the ingestion of the medication on their smartphone.READ MORE: Cancer gene still alive in body after death; could be transplanted through organ donation: studyAbout the size of a grain of salt, the sensor has no battery or antenna and is activated when it gets wet from stomach juices. That completes a circuit between coatings of copper and magnesium on either side, generating a tiny electric charge.In the longer term, such digital pills could also be used to manage patients with other complicated medicine routines, such as those suffering from diabetes or heart conditions.Poor compliance with drug regimens is a common problem in many disease areas, especially when patients suffer from chronic conditions.Proteus has been working on the pill tracking system for many years and the sensor used in Abilify MyCite was first cleared for use by the FDA in 2012.
© 2017 Reuters
Trending
-
Boeing 737 Max whistleblower Joshua Dean, 45, dead after sudden illness17212 Read
-
Toddler, 2, dies after bouncy castle carried away by strong wind14920 Read
-
As Loblaw boycott begins, what to know about all the company’s brands10229 Read
-
Canada’s dental plan has officially kicked in. Who is eligible?9823 Read
-
Mandatory breath samples now required in every Toronto-area traffic stop: OPP5678 Read
-
London Drugs remains closed, says it is reviewing billions of lines of data4396 Read
You are viewing an Accelerated Mobile Webpage.
View Original Article